Treatment-resistant depression occurs when symptoms persist after multiple antidepressant treatments
Rapid-acting antidepressants, such as ketamine and psilocybin, can work quickly for some patients, but clinicians lack biomarkers to predict response
Researchers found shared immune-related signals across rapid-acting antidepressants, and these biomarkers may help guide future treatment strategies
HOUSTON, JULY 30, 2026 ― In a new study, researchers from The University of Texas MD Anderson Cancer Center have uncovered insights that may help explain how rapid-acting antidepressants, such as ketamine and psychedelics, can reduce symptoms in difficult-to-treat depression. The findings may also help identify patients who are most likely to benefit from these treatments.
The study, published in Molecular Psychiatry , was co-led by Gregory Jones, M.D., assistant professor of Psychiatry . The researchers discovered that these therapies work by changing communication signals between the immune system and the brain, suggesting that they share certain neuroimmune pathways, even though they act on different receptors in the brain.
“Ketamine and psychedelics affect the brain in different ways subjectively, but our findings suggest that they eventually end up in some of the same neuroimmune pathways,” Jones said. “By studying blood signals and brain activity together, researchers can better understand how the body and brain may work in tandem to respond to antidepressants. We hope to be able to use these findings to better treat patients with depression, which is not uncommon in those facing a cancer diagnosis.”
Treatment-resistant depression occurs when symptoms do not improve after multiple treatments with traditional antidepressants or talk therapy. Rapid-acting antidepressants, such as ketamine and psilocybin, have demonstrated significant, rapid symptom improvement in some patients with treatment-resistant depression, but it is unclear which patients are more likely to benefit. A deeper understanding of the biological mechanisms driving these responses could help scientists develop more durable and accessible treatments for depression.
The researchers analyzed the effects of multiple rapid-acting antidepressants in laboratory models as well as in a previous clinical trial. They discovered that several rapid-acting antidepressants trigger a common set of molecular changes related to the immune system in brain cells. They observed matching immune-related changes in patients' blood along with related shifts in patients' brain electrical activity after ketamine treatment, suggesting a shared biological pathway that may underlie rapid relief from depression.
Participants who responded to ketamine showed lower IL-15 pathway activity and higher B cell signaling before treatment than nonresponders, both of which reversed after treatment in patients who responded. The results suggest that rapid antidepressant response may involve restoring balance between IL-7 and IL-15, with downstream effects on B cells and brain activity.
The findings are exploratory and need validation in larger, prospective studies. Future research will determine whether IL-15, IL-7 and related biomarkers can predict treatment response before therapy and whether targeting these pathways could improve or extend responses to rapid-acting antidepressants.
***
This research was funded in part by the National Institutes of Health. For a full list of collaborating authors, disclosures and funding sources, see the full paper in Molecular Psychiatry .
Molecular Psychiatry
Randomized controlled/clinical trial
People
Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics
28-Jul-2026